Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2017 | What is the best treatment for RAS wild-type metastatic colorectal cancer?

Alfredo Carrato • 8 Sep 2017
ESMO 2017
Colorectal Cancer Bevacizumab FOLFOXIRI Panitumumab

Alfredo Carrato, MD, PhD, Ramon y Cajal University Hospital, Madrid, Spain, describes interesting trials discussed at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. An interesting trial presented this year investigated FOLFOXIRI plus panitumumab (NCT01358812). It found a high response rate in patients with RAS wild-type metastatic colorectal cancer. Another interesting trial investigated whether to add an EGFR inhibitor after treatment with bevacizumab in RAS wild-type colorectal cancer showed that bevacizumab conferred an improvement in progression free survival.

More from Alfredo Carrato

2:30
Manipulating the microbiome of patients with pancreatic cancer to increase response to treatment
Alfredo Carrato • 5 Jun 2022
1:50
Methods for the early diagnosis of pancreatic cancer
Alfredo Carrato • 5 Jun 2022
0:53
Second-line treatment strategies for pancreatic cancer
Alfredo Carrato • 5 Jun 2022
2:45
SEQUENCE: nab-paclitaxel/gemcitabine with modified FOLFOX in pancreatic cancer
Alfredo Carrato • 5 Jun 2022

Related Videos

0:47
The key to precision medicine in colorectal cancer
Scott Kopetz • 8 Apr 2024
0:40
Clinical targeting of adaptive resistance in colorectal cancer
Scott Kopetz • 8 Apr 2024
1:47
Adaptive resistance in BRAF- and KRAS-mutated colorectal cancer
Scott Kopetz • 8 Apr 2024
1:19
How can we implement MRD testing in colorectal cancer?
Paolo Manca • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals